Impact of MET inhibition on small‐cell lung cancer cells showing aberrant activation of the hepatocyte growth factor/MET pathway

Small‐cell lung cancer (SCLC) accounts for approximately 15% of all lung cancers, and is characterized as extremely aggressive, often displaying rapid tumor growth and multiple organ metastases. In addition, the clinical outcome of SCLC patients is poor due to early relapse and acquired resistance t...

Descripción completa

Detalles Bibliográficos
Autores principales: Taniguchi, Hirokazu, Yamada, Tadaaki, Takeuchi, Shinji, Arai, Sachiko, Fukuda, Koji, Sakamoto, Shuichi, Kawada, Manabu, Yamaguchi, Hiroyuki, Mukae, Hiroshi, Yano, Seiji
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2017
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5497807/
https://www.ncbi.nlm.nih.gov/pubmed/28474864
http://dx.doi.org/10.1111/cas.13268

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5497807/
https://www.ncbi.nlm.nih.gov/pubmed/28474864
http://dx.doi.org/10.1111/cas.13268

Ejemplares similares